Cervical Cancer

These rhenium(I) tricarbonyl complexes also slightly increased ROS production and significantly decreased the mitochondrial membrane potential by 50 % (5eRe) and 45 % (6dRe) compared to untreated cells and cells treated with 5e and 6d. These results suggest that the cytotoxic effects of these compounds are mediated by their effects on mitochondrial membrane potential and the subsequent increase in ROS production.

Des-[Arg9]-Leu8-BK and HOE-140 were used as antagonists for the B1 and B2 receptors...Moreover, the migration and invasion induced by kinins in breast cancer cells were inhibited when focal adhesion kinase (FAK) and Src inhibitors were used. The novelty revealed in our work is that B1 and B2 receptors activated by LDBK and BK induce migration and invasion in breast cancer cells via a mechanism that involves the FAK-Src signaling pathway, and the antagonism of both receptors in vivo impairs breast tumor growth.

Our results indicate that adenocarcinomas of intestinal-type, in distal vagina or vestibular vulva, might be a unique and single entity, probably originating from cloacogenic embryonic remnants and/or ectopic colorectal mucosae inclusions. An open question would be to explore the efficacy of systemic drugs prescribed in colorectal cancers, in VVAIts.

PLOD2 exerted pro‑oncogenic effects on CESC through the p53 pathway by binding to YAP1. These findings provide new perspectives for the future study of PLOD2‑targeted therapy for CESC.

circSTX6 may be a clinical prognostic biomarker in CSCC. The absence of circSTX6 inhibits cellular behaviors and increases the sensitivity of cervical cancer cells to radiation by modulating miR-203a-3p/RAB27B axis.

New biomarkers for the prognosis of cervical cancer are also reported in this study. Moreover, identifying specific genes within the regulatory networks provides valuable insights into potential therapeutic targets for managing cervical cancer.

Collectively, ITGA3 is a marker of poor prognosis and promotes tumor progression by regulating PI3K/AKT pathway in cervical cancer. Our results provide new insights for potential molecular targeted therapy and prognostic prediction of cervical cancer.

Two gene expression profiles of GSE9750 and GSE6791, which included cervical cancer HPV-positive and -negative samples, were evaluated using the R limma package with established cut-off criteria of P value < 0.05 and | fold change| ≥ 1...In fact, the current study has the potential to give a distinct viewpoint on the molecular pathways linked to cervical cancer. Considering the potential importance of the hub genes, we recommend conducting in-depth wet lab research to determine their impact on the biological mechanisms of cervical cancer.

Inhibition of CCL22 protein significantly decreased migration of CC cells and vimentin, slug, snail and β-catenin levels, while ZO-1 increased. In conclusion, EZH2 appears to regulate CCL22/CCR4 expression via epigenetic activation, causing EMT process remodeling in CC progression.

This study demonstrated that opt-in HPV self-sampling among 24-year-old women who had never been screened for cervical cancer had a favorable kit return rate and was well accepted by the participants, especially during the COVID-19 pandemic. However, the follow-up cytology test rates were low, highlighting the need for improved post-screening management.

Overall, the correlation between CD59 and immune cells predicts its prognosis as unfavorable in CESC, GBM, HNSC, and STAD while being favorable in KIRC.

Importantly, F5 CAR-T cells inhibited the growth of CaSki and SS4050 tumor xenografts in mice. These findings demonstrate that HPV-16+ cervical cancer can be targeted by F5 nanobody-based CAR-T cells, offering a valuable alternative strategy for treating HPV-16+ malignancies.

No abstract available

Seven miRNAs may serve as prognostic biomarkers of cervical squamous cell carcinoma. SLC2A1, ANO6, and TXNIP are associated with cervical squamous cell carcinoma and may serve as ferroptosis-related markers of the disease.

P1/2, N=316, Recruiting, Simcha IL-18, Inc. | Active, not recruiting --> Recruiting | Trial completion date: Jan 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Jun 2025

P1, N=26, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Nov 2024 | Trial primary completion date: Apr 2025 --> Nov 2024

HIV is an independent risk factor for cervical HSIL recurrence and reduced disease-free survival time. Glandular involvement, compromised margins, undetectable CV and CD4<200 also increase the risk of relapse.

Finally, we confirmed that METTL14-modified HOXB13 exerted an oncogenic effect through activation of the nuclear factor kappa B (NF-κB) pathway. In conclusion, our data demonstrated that the m6A modification of HOXB13, mediated by METTL14, facilitated the advancement of CC through targeting the NF-κB pathway, which may be a potential molecular target for the treatment of CC.

Endocervical adenocarcinomas with micropapillary components are associated with aggressive clinical behavior and a poor prognosis, which can be found in various conventional histological types of ECAs regardless of the HPV status. The high prevalence of PD-L1 expression suggests that patients with micropapillary ECAs may be good candidates for PD-L1 inhibitor treatment.

The upregulation of HDAC6 induced by METTL3 over-expression is capable of inhibiting cilia elongation and acetylation of α-tubulin, thereby shortening cilia length and accelerating the progression of cervical cancer both in vitro and in vivo. Collectively, depletion of METTL3-mediated m6A modification leads to abnormally elongated cilia via suppressing HDAC6-dependent deacetylation of axonemal α-tubulin, ultimately attenuating cell growth and cervical cancer development.

P=N/A, N=145, Completed, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Completed | Trial completion date: Nov 2025 --> Jul 2024 | Trial primary completion date: Oct 2024 --> Jun 2024

In the Screening population, Group A HPV52 and Group B HPV68 had the highest prevalence among the sequenced samples. In the Enriched population, Group A HPV52 again had the highest prevalence, whereas HPV56 had the highest prevalence in the Group B.

These data demonstrate the differences in HR HPV genotype prevalence for the African American population compared to the total study population in a large U.S. clinical study. Despite the differences in genotype distribution, the Alinity m HR HPV assay demonstrated 100.0% (95% CI, 74.1%, 100.0%) sensitivity for African American women with cervical precancer and cancer.

In this study, HPV18 demonstrated the highest median difference between ≥CIN3 and ≤CIN1 (3.82 CN), followed by HPV16 (2.96 CN), Group A (2.53 CN), HPV 45 (2.23 CN), and Group B (2.09 CN).

Due to variable HPV vaccination uptake rates, HPV molecular tests used for cervical cancer screening must be able to detect cervical dysplasia regardless of vaccine status. These data demonstrate that the clinical sensitivity of the Alinity m HR HPV assay for the detection of cervical dysplasia is equivalent to the cobas HPV test in both vaccinated and unvaccinated populations.

In this study, analytical and clinical studies demonstrate that self-collected vaginal specimens can be utilized for routine cervical cancer screening with the Alinity m HR HPV assay.

P2, N=85, Recruiting, Baylor College of Medicine

P=N/A, N=1066, Recruiting, University of Aarhus | Trial completion date: Aug 2026 --> Jul 2025 | Trial primary completion date: Mar 2026 --> Jul 2025

P=N/A, N=480, Recruiting, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; National Cancer Center/Cancer Hospital,

P=N/A, N=108, Recruiting, SCIENCES ZHEJIANG CANCER HOSPITAL; Leadbio Biotechnology (Hangzhou) Co., Ltd

P=N/A, N=500, Not yet recruiting, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital; Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital

P=N/A, N=40, Not yet recruiting, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital，Chinese Academy of Medical Sciences and

P=N/A, N=150, Not yet recruiting, Sun Yat-sen Memorial Hospital of Sun Yat-sen University; Sun Yat-sen Memorial Hospital of Sun Yat-sen University

P=N/A, N=30, Recruiting, Capital Medical University Cancer Canter, Beijing Shijitan Hospital; Beijing Shijitan Hospital

P=N/A, N=129, Recruiting, The Second Affiliated Hospital of Zunyi Medical University; The Second Affiliated Hospital of Zunyi Medical University

P=N/A, N=60, Recruiting, Guangzhou Women and Children's Medical Center, Guangzhou Medical University; Guangzhou Women and Children's Medical Center, Guangzhou Medical Universi

P=N/A, N=1000, Not yet recruiting, Shanghai General Hospital; Shanghai General Hospital

P=N/A, N=320, Recruiting, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital); Huazhong University of Science and Technology Union Shenzhen

P=N/A, N=75, Not yet recruiting, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine; Shanghai First Maternity and Infant Hospital, Tongji University Sc

P=N/A, N=0, Recruiting, chongqing university cancer hospital; chongqing university cancer hospital

P4, N=50, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of

P4, N=34, Not yet recruiting, Chinese PLA General Hospital; Chinese PLA General Hospital